Soligenix recently announced an exciting update for its novel skin cancer treatment. The company reports that its flagship product candidate, HyBryte™, is showing impressive results in treating a rare form of skin cancer called cutaneous T-cell lymphoma or CTCL, with 75% of patients seeing significant improvement after just 18 weeks.
00:00Soligenix, which trades under the ticker symbol SNGX on the NASDAQ, recently announced an exciting update for its novel skin cancer treatment.
00:11The company reports that its flagship product candidate, Hybrite, is showing impressive results in treating a rare form of skin cancer called cutaneous T-cell lymphoma, or CTCL, with 75% of patients seeing significant improvement after just 18 weeks.
00:28The treatment appears to be working well in real-world testing. Of the eight patients evaluated so far, six showed major improvement in their skin lesions.
00:37Even more impressive, Soligenix reports that three patients achieved a complete response, meaning their lesions essentially disappeared.
00:45For patients who completed the full 54-week treatment, the average improvement was a substantial 85%.
00:51Unlike many current treatments that can take 6 to 12 months to work and often have serious side effects,
00:57Hybrite so far appears to work faster, showing results at 18 weeks, and appears much safer.
01:03It uses visible light rather than harmful UV radiation, significantly reducing the risk of causing new cancers, which is a common problem with existing treatments.
01:12Dr. Ellen Kim of the University of Pennsylvania, who's leading the study, expressed excitement about the consistent results and safety profile across multiple clinical trials.
01:22The FDA recognizes the potential here too. They're funding this study with a $2.6 million grant through their Orphan Products Development Program.
01:32For investors, several potential catalysts to watch for are lining up. The company is now enrolling patients in its confirmatory Phase 3 Flash 2 trial.
01:41Results continue supporting Hybrite as potentially the first safe, frontline treatment for this disease.
01:48The therapy could expand into home use, making it more convenient for patients.
01:53The market opportunity is significant despite CTCL being rare.
01:58With approximately 31,000 patients in the U.S. and 38,000 in Europe, and very few effective treatment options available,
02:06Hybrite could capture substantial market share if approved.
02:10SNGX represents a late-stage company with promising clinical data, government funding support,
02:17and a clear path toward potentially bringing a safer, more effective treatment to market for an underserved patient population.
02:28A
02:38federal government funding for the public health company will be recognized by receiving the U.S. and 30,000 patients.
02:44The plan for lights are designed to be recognized by one of thebright-connected and U.S. and 31 participants across the country,
02:48and a career of their own new happiness.
02:52It's official and federal government funding for the U.S. and 30,000 patients.
